| Observational study: prospective longitudinal cohort  

Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register

Impact on neurological comorbidities

In this paper, recently published in the Journal of Neurology, Neurosurgery and Psychiatry, the authors report initial findings of an ongoing community based COVID-19 study in a large UK-wide population of people with multiple sclerosis (pwMS) which coincided with the peak of the COVID-19 outbreak in the UK.

The authors show that pwMS taking immunomodulatory treatments do not have an increased risk of contracting COVID-19. Moreover they did not find individual disease-modifying therapies (DMTs) to be noticeably over-represented among pwMS with COVID-19. They concluded that, during a period with strict precautions in place to prevent the spread of COVID-19, pwMS and those taking DMTs are not at an increased risk of contracting the disease.

http://dx.doi.org/10.1136/jnnp-2020-324449

Back